ArticleCellular and molecular life sciences : CMLS2026
Identification of alterations of immunometabolism associated with Pompe disease.
Article in Cellular and molecular life sciences : CMLS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Identifying regulatory muscle processes in infantile and adult Pompe patients using a multi-omic and morphological approach.Brain pathology (Zurich, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
Pompe disease (PD) is a neuromuscular lysosomal storage disorder caused by mutations in the GAA gene, characterized by progressive glycogen accumulation in multiple tissues and autophagy and metabolic abnormalities. While immunological changes have largely been overlooked as part of PD's symptomatology, autophagy and metabolic regulation are crucial in immune cell function. High incidence of immune reactions against therapeutic recombinant GAA (rhGAA) in PD patients suppose an important hindrance to treatment efficacy, yet the impact of GAA deficiency on the immune system remains unclear. Here we explored the T cell phenotype in late-onset PD patient cells and in a PD mouse model, revealing heightened expression of activation markers in effector T cells compared to controls. Additionally, we observed decreased frequencies of regulatory T cells in mice. We also hypothesized that metabolic and autophagy defects in PD extend to immune cells. In fact, Gaa−/− T cells reproduced autophagy and mitophagy defects reported in muscle cells, and upon stimulation, T cells showed impaired mitochondrial function consistent with defective mitophagy. Preliminary findings also suggest that alterations translate to a subset of CD24+CD172− conventional dendritic cells with regulatory function, which could indirectly contribute to higher T cell activation. Our observations indicate that immune homeostasis is altered in PD, offering new insights on immune dysfunction in the context of lysosomal impairment and providing the rationale for investigating its potential role in the pathogenesis of PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.